AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9862651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation (1 x 10^10 colony forming units/day)
Number of subjects: 39
Study 9862651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9862651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri supplementation
Number of subjects: 39
Study 7657446 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% nicotinamide gel
Number of subjects: 76
Study 7657446 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin gel
Number of subjects: 76
Study 2697239 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 10 mg
Number of subjects: 40
Study 2697239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study 2697239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 40
Study 2697239 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 5 mg
Number of subjects: 40
Study 2697239 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 972208 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral contracting services offered at home and in school
Number of subjects: 102
Study 972208 — intervention group
Group type: COMPARATOR
Intervention: Control condition with no behavioral contracting services
Number of subjects: 102
Study 31543950 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone treatment (MHT) started within 5 to 10 years of menopause
Number of subjects: 0
Study 31543950 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment (ET) for women undergoing premature menopause
Number of subjects: 0
Study 31543950 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone treatment (MHT) for normal women
Number of subjects: 0
Study 28499728 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin push alerts to physician smartphones
Number of subjects: 1554
Study 28499728 — intervention group
Group type: COMPARATOR
Intervention: No troponin push alerts
Number of subjects: 1554
Study 26413574 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day Korean red ginseng for 4 weeks
Number of subjects: 61
Study 26413574 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 mg/day Korean red ginseng for 4 weeks
Number of subjects: 61
Study 26413574 — intervention group
Group type: COMPARATOR
Intervention: 160 mg/day Ginkgo biloba extract for 4 weeks
Number of subjects: 61
Study 23432431 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT)
Number of subjects: 143
Study 23432431 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 143
Study 22077928 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate protein supplement (24 g daily for 8 weeks)
Number of subjects: 90
Study 22077928 — intervention group
Group type: COMPARATOR
Intervention: Milk protein supplement (24 g daily for 8 weeks)
Number of subjects: 90
Study 19917449 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan (5.5 g)
Number of subjects: 14
Study 19917449 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan (2.2 g to 5.5 g)
Number of subjects: 14
Study 19917449 — intervention group
Group type: COMPARATOR
Intervention: Control meal
Number of subjects: 14
Study 19917449 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucan (various doses)
Number of subjects: 14
Study 17030521 — intervention group
Group type: EXPERIMENTAL
Intervention: Caldaret 57.5 mg (lower dose)
Number of subjects: 387
Study 17030521 — intervention group
Group type: EXPERIMENTAL
Intervention: Caldaret 172.5 mg (higher dose)
Number of subjects: 387
Study 17030521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study 12622853 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Number of subjects: 73
Study 12622853 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste
Number of subjects: 73
Study 11043885 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 0
Study 11043885 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 0
Study 8858533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (combinations of Adriamycin and Dacarbazine or Ifosfamide and Mesna)
Number of subjects: 0
Study 8858533 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (interferon‐alpha)
Number of subjects: 0
Study 8858533 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 8858533 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 8858533 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 0
Study 1536112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical sternal lead
Number of subjects: 50
Study 6391162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sucrose diet (less than 3 g of sucrose)
Number of subjects: 0
Study 6391162 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sucrose diet (220 g of sucrose)
Number of subjects: 0
Study 6391162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-sucrose diet (120 g of sucrose)
Number of subjects: 0
Study 6391162 — intervention group
Group type: COMPARATOR
Intervention: Control diet (120 g of sucrose and 50 percent carbohydrate)
Number of subjects: 0
Study 31986325 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozone therapy (ozone hydrotherapy followed by ozonated oil)
Number of subjects: 0
Study 31986325 — intervention group
Group type: COMPARATOR
Intervention: Control (tap water and basal oil)
Number of subjects: 0
Study 31986325 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ozone therapy
Number of subjects: 0
Study 30382930 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body neuromuscular electrical stimulation (WBS)
Number of subjects: 36
Study 30382930 — intervention group
Group type: COMPARATOR
Intervention: Sham (control)
Number of subjects: 36
Study 27776673 — intervention group
Group type: EXPERIMENTAL
Intervention: READY First (Motivational Interviewing intervention)
Number of subjects: 244
Study 27776673 — intervention group
Group type: COMPARATOR
Intervention: WLC (Waitlist Control)
Number of subjects: 244
Study 27776673 — intervention group
Group type: EXPERIMENTAL
Intervention: READY First
Number of subjects: 244
Study 27776673 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 244
Study 24576855 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h aerobic exercise session (LA)
Number of subjects: 8
Study 24576855 — intervention group
Group type: COMPARATOR
Intervention: 1-h aerobic exercise session (MA)
Number of subjects: 8
Study 24576855 — intervention group
Group type: COMPARATOR
Intervention: 1-h resistance exercise session (MR)
Number of subjects: 8
Study 24576855 — intervention group
Group type: COMPARATOR
Intervention: 2-h resistance exercise session (LR)
Number of subjects: 8
Study 24576855 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise; CON)
Number of subjects: 8
Study 22153696 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids 2 g daily for 2 months
Number of subjects: 150
Study 22153696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 160 mg daily for 2 months
Number of subjects: 150
Study 22153696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 20167147 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC, 100/50 micrograms twice daily
Number of subjects: 1385
Study 20167147 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC twice daily + FPANS, 200 micrograms once daily
Number of subjects: 1385
Study 20167147 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC twice daily + MON, 10 mg once daily
Number of subjects: 1385
Study 20167147 — intervention group
Group type: COMPARATOR
Intervention: MON once daily
Number of subjects: 1385
Study 17912226 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 0
Study 16288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (DC)
Number of subjects: 401
Study 16288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-carboplatin (DCb)
Number of subjects: 401
Study 16288485 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 401
Study 16288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of elderly patients to younger patients
Number of subjects: 401
Study 16288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity profile
Number of subjects: 401
Study 16288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutropenia
Number of subjects: 401
Study 11884912 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric axial rotation exertion at 80% maximum voluntary contraction
Number of subjects: 24
Study 10707139 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated system for the measurement of erythrocyte sedimentation rate (ESR)
Number of subjects: 212
Study 10707139 — intervention group
Group type: COMPARATOR
Intervention: Manual Seditainer method
Number of subjects: 212
Study 8950773 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 188
Study 8950773 — intervention group
Group type: EXPERIMENTAL
Intervention: Danaparoid
Number of subjects: 188
Study 8950773 — intervention group
Group type: COMPARATOR
Intervention: Utrecht bleeding risk score
Number of subjects: 188
Study 8950773 — intervention group
Group type: COMPARATOR
Intervention: Landefeld bleeding risk index
Number of subjects: 188
Study 2013485 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 3234
Study 2013485 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 3234
Study 7036726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg per day
Number of subjects: 48
Study 7036726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg per day
Number of subjects: 48
Study 7036726 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg and 240 mg
Number of subjects: 48
Study 29463913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 5.0 mg
Number of subjects: 18
Study 29463913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 2.5 mg + active cannabis (5.6% THC)
Number of subjects: 18
Study 29463913 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 2.5 mg
Number of subjects: 18
Study 29463913 — intervention group
Group type: COMPARATOR
Intervention: Active cannabis
Number of subjects: 18
Study 29463913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone + cannabis
Number of subjects: 18
Study 27869110 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced audio serial addition task (PASAT)
Number of subjects: 15
Study 27869110 — intervention group
Group type: COMPARATOR
Intervention: Neutral intervention (peaceful music)
Number of subjects: 15
Study 25765671 — intervention group
Group type: EXPERIMENTAL
Intervention: 25g whey preload
Number of subjects: 0
Study 25765671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24331680 — intervention group
Group type: EXPERIMENTAL
Intervention: Choose Health program (cognitive behavioural lifestyle intervention)
Number of subjects: 63
Study 24331680 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 63
Study 20142658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a median dose of 81.5 microg/kg
Number of subjects: 272
Study 18566863 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific oral anticoagulation treatment educational program
Number of subjects: 0
Study 18566863 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific educational program)
Number of subjects: 0
Study 18566863 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 0
Study 16629421 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNbeta-1a, Avonex) 60 microg weekly intramuscular injections for 24 months
Number of subjects: 0
Study 16629421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14762699 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-131 therapy (1.8-10.4 GBq single activity, 5.5-43.7 GBq total activity) after total thyroidectomy and lymph node dissection if applicable
Number of subjects: 42
Study 14762699 — intervention group
Group type: COMPARATOR
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 42
Study 10730072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboral pouch construction
Number of subjects: 25
Study 10730072 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction
Number of subjects: 25
Study 9186348 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 40
Study 9186348 — intervention group
Group type: COMPARATOR
Intervention: Flutamide
Number of subjects: 40
Study 9186348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study 8266015 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up intervals varying from 6 to 48 months (with 53 patients allocated to 6 months)
Number of subjects: 1056
Study 8266015 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up strategy
Number of subjects: 1056
Study 8266015 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy examinations
Number of subjects: 1056
Study 8266015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma-carcinoma conversion rates
Number of subjects: 1056
Study 4039155 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine (100 mg, 3 consecutive doses)
Number of subjects: 12
Study 4039155 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (50 mg, single dose)
Number of subjects: 12
Study 4039155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2906876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 20 mg
Number of subjects: 8
Study 2906876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 40 mg
Number of subjects: 8
Study 2906876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine 80 mg
Number of subjects: 8
Study 2906876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29614679 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite supplement containing astaxanthin and sesamin (AS)
Number of subjects: 21
Study 29614679 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 21
Study 27869113 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) for 8 weeks, 4-6 sets of 20 seconds at maximal intensity with a ratio effort/recovery of 1:3 to 1:1
Number of subjects: 35
Study 27869113 — intervention group
Group type: COMPARATOR
Intervention: Continuous aerobic exercise for 8 weeks
Number of subjects: 35
Study 24563922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine (CP) 40 mg intrathecally with 500 ml pre-load (CP+)
Number of subjects: 100
Study 24563922 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine (CP) 40 mg intrathecally without pre-load (CP−)
Number of subjects: 100
Study 24563922 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L) 60 mg intrathecally with 500 ml pre-load (L+)
Number of subjects: 100
Study 24563922 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (L) 60 mg intrathecally without pre-load (L−)
Number of subjects: 100
Study 23656510 — intervention group
Group type: EXPERIMENTAL
Intervention: computerized cognitive remediation
Number of subjects: 28
Study 23656510 — intervention group
Group type: EXPERIMENTAL
Intervention: games
Number of subjects: 28
Study 20703256 — intervention group
Group type: EXPERIMENTAL
Intervention: p190 ALL
Number of subjects: 82
Study 20703256 — intervention group
Group type: EXPERIMENTAL
Intervention: p210 ALL
Number of subjects: 82
Study 20703256 — intervention group
Group type: COMPARATOR
Intervention: p210 CML
Number of subjects: 82
Study 18622274 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 18622274 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 0
Study 17099426 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental plantar flexion exercise at 2, 3, 4, and 5 W
Number of subjects: 12
Study 17099426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle brachial pressure index measurement
Number of subjects: 12
Study 17099426 — intervention group
Group type: EXPERIMENTAL
Intervention: Run-off resistance determined on MR angiograms
Number of subjects: 12
Study 14633959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus somatostatin 250 microg given immediately after diagnostic cholangiopancreatography
Number of subjects: 270
Study 14633959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 10966906 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (50 g carbohydrate)
Number of subjects: 20
Study 10966906 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes (50 g carbohydrate)
Number of subjects: 20
Study 10966906 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley (50 g carbohydrate)
Number of subjects: 20
Study 10966906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9356550 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides
Number of subjects: 15
Study 9356550 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 15
Study 9356550 — intervention group
Group type: COMPARATOR
Intervention: Glucose (placebo)
Number of subjects: 15
Study 8470531 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (two pieces of Scopoderm-TTS patches)
Number of subjects: 0
Study 8470531 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 0
Study 3511703 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet combined with antiandrogenic therapy (cyproterone acetate, 50 mg/day, plus ethinyl estradiol, 0.05 mg/day)
Number of subjects: 0
Study 3511703 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet without antiandrogenic therapy
Number of subjects: 0
Study 30932951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 9322
Study 30932951 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 9322
Study 30932951 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 9322
Study 30932951 — intervention group
Group type: COMPARATOR
Intervention: TDF
Number of subjects: 9322
Study 29262272 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR+CAFF
Number of subjects: 8
Study 29262272 — intervention group
Group type: COMPARATOR
Intervention: CMR
Number of subjects: 8
Study 29262272 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 8
Study 26806591 — intervention group
Group type: EXPERIMENTAL
Intervention: Endodontic debridement
Number of subjects: 95
Study 26806591 — intervention group
Group type: COMPARATOR
Intervention: No endodontic debridement
Number of subjects: 95
Study 24102369 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL‐PDT
Number of subjects: 21
Study 24102369 — intervention group
Group type: COMPARATOR
Intervention: MAL‐PDT
Number of subjects: 21
Study 23030656 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery
Number of subjects: 19
Study 23030656 — intervention group
Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 19
Study 23030656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both recovery types
Number of subjects: 19
Study 20413988 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Escherichia coli strain administered (1 mL within 48 hours after birth, then 3 times a week for 4 weeks)
Number of subjects: 158
Study 20413988 — intervention group
Group type: COMPARATOR
Intervention: Control infants of allergic mothers
Number of subjects: 158
Study 20413988 — intervention group
Group type: COMPARATOR
Intervention: Control infants of healthy mothers
Number of subjects: 158
Study 18687167 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino-bisphosphonates treatment
Number of subjects: 234
Study 16483520 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of SF-36
Number of subjects: 351
Study 16483520 — intervention group
Group type: COMPARATOR
Intervention: Self-administration of SF-36
Number of subjects: 351
Study 11954988 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm methyl ethyl ketone exposure
Number of subjects: 19
Study 11954988 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 19
Study 10981547 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 72
Study 10981547 — intervention group
Group type: COMPARATOR
Intervention: ACEI (enalapril)
Number of subjects: 72
Study 8955865 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium molecular weight (MMW) hydroxyethyl starch (HES) 200/0.5
Number of subjects: 20
Study 8955865 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW) hydroxyethyl starch (HES) 40/0.5
Number of subjects: 20
Study 1488514 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg (t.i.d.)
Number of subjects: 8
Study 1488514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3929692 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful alone
Number of subjects: 0
Study 3929692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of MMC and Futraful
Number of subjects: 0
Study 3929692 — intervention group
Group type: COMPARATOR
Intervention: MMC alone
Number of subjects: 0
Study 30994192 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPP
Number of subjects: 251
Study 30994192 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein
Number of subjects: 251
Study 30994192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIPP and Lichtenstein
Number of subjects: 251
Study 28193189 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose DHA supplementation (1000 mg DHA/d)
Number of subjects: 1200
Study 28193189 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 mg DHA/d from prenatal supplement)
Number of subjects: 1200